GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oyster Point Pharma Inc (NAS:OYST) » Definitions » Goodwill

Oyster Point Pharma (Oyster Point Pharma) Goodwill : $0.00 Mil (As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Oyster Point Pharma Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Oyster Point Pharma's goodwill for the quarter that ended in Sep. 2022 was $0.00 Mil.


Oyster Point Pharma Goodwill Historical Data

The historical data trend for Oyster Point Pharma's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oyster Point Pharma Goodwill Chart

Oyster Point Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
Goodwill
- - - - -

Oyster Point Pharma Quarterly Data
Dec17 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oyster Point Pharma Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Oyster Point Pharma  (NAS:OYST) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Oyster Point Pharma's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Goodwill-to-Asset (A: Dec. 2021 )=Goodwill/Total Assets
=0/222.617
=0.00

Oyster Point Pharma's Goodwill-to-Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

Goodwill-to-Asset (Q: Sep. 2022 )=Goodwill/Total Assets
=0/109.201
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Oyster Point Pharma Goodwill Related Terms

Thank you for viewing the detailed overview of Oyster Point Pharma's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Oyster Point Pharma (Oyster Point Pharma) Business Description

Traded in Other Exchanges
N/A
Address
202 Carnegie Center, Suite 109, Princeton, NJ, USA, 08540
Oyster Point Pharma Inc is a biopharmaceutical company focused on the development of pharmaceutical therapies to treat ocular surface diseases. Its product candidate OC-01 is a nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.
Executives
Ozawa Clare director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Donald J Santel director 4362 24TH STREET, SAN FRANCISCO CA 94114
George Christopher Eliades director C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Michael G Atieh director MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
John Snisarenko officer: Chief Commercial Officer C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Invopps Gp Iv, L.l.c. director, 10 percent owner 126 EAST 56TH STREET, 20THFLOOR, NEW YORK NY 10022
Vida Ventures, Llc 10 percent owner 40 BROAD STREET, SUITE 201, BOSTON MA 02109
Kkr Healthcare Strategic Growth Fund L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Jeffrey Nau director, officer: President and CEO 202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
Daniel Lochner officer: Chief Financial Officer 202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Kkr Group Partnership L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001
Invopps Iv Us, L.p. director, 10 percent owner 126 EAST 56TH STREET, 20TH FLOOR, NEW YORK NY 10022

Oyster Point Pharma (Oyster Point Pharma) Headlines